Tecentriq 1200mg Injection may be prescribed for certain types of cancer, including:

• Non-small cell lung cancer (NSCLC): It may be used alone or with other cancer medicines, depending on the type and stage of the cancer and the patient's treatment plan.

• Small cell lung cancer (SCLC): It may be used with other anticancer medicines in selected patients.

• Hepatocellular carcinoma (HCC): It may be used with Bevacizumab in selected patients with advanced liver cancer.

The exact treatment combination and schedule depend on the cancer type, stage and previous treatment.

Tecentriq 1200mg Injection contains Atezolizumab, a PD-L1 inhibitor. PD-L1 is a protein that can help cancer cells avoid attack by the immune system.

Atezolizumab blocks PD-L1, helping immune cells recognise and attack cancer cells.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Other anticancer medicines: Tell your doctor about all chemotherapy, targeted medicines and immunotherapies you are receiving. Treatment combinations need to be planned by your oncology team.

• Corticosteroids or other medicines affecting the immune system: These may affect the way immune-related reactions are managed.

• Organ transplant medicines: Tell your doctor if you have received or may require an organ transplant, as immune checkpoint inhibitors can increase the risk of transplant-related complications.

Do not start, stop or change any medicine during treatment without medical advice.

• Store Tecentriq 1200mg Injection in a refrigerator at 2°C to 8°C.

• Keep it in the original carton and protect it from light.

• Do not freeze.

• Do not shake.

• The medicine should be prepared and administered by trained healthcare professionals according to the product instructions.

Tecentriq 1200mg Injection is given intravenously as an infusion by a healthcare professional.

The 1200mg strength is used as part of treatment schedules selected according to the cancer being treated. It may be given once every 3 weeks in some treatment regimens. The infusion time and treatment duration are decided by the oncologist.

Do not try to administer Tecentriq 1200mg Injection yourself.

Common side effects

• Fatigue

• Decreased appetite

• Nausea

• Cough

• Shortness of breath

• Diarrhoea

• Constipation

• Hair loss when used with chemotherapy

• Skin rash

• Muscle or joint pain

Serious side effects

Seek medical attention if you develop:

• Severe or persistent breathing difficulty or cough

• Severe diarrhoea or abdominal pain

• Yellowing of the skin or eyes

• Severe rash or skin reactions

• Reduced urine output or swelling

• Severe weakness, dizziness or changes in hormone-related symptoms

• Symptoms of an infusion-related reaction

Tecentriq can cause immune-mediated inflammation affecting different organs. These reactions may require treatment interruption or discontinuation.

• Attend all scheduled blood tests and oncology appointments.

• Report new symptoms early, even if they seem mild.

• Keep a list of all medicines and supplements you take.

• Tell your doctor if you have an autoimmune condition or have received an organ transplant.

• Do not stop cancer treatment or supportive medicines without medical advice.

• Inform your healthcare team before receiving any vaccination.